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Abstract
Rationale: Chronic obstructive pulmonary disease (COPD) is characterized by lung and systemic
inflammation. The role of cytokines in local and systemic inflammation in COPD is not well understood.
This study aimed to compare plasma and bronchoalveolar lavage (BAL) fluid cytokine levels in COPD
and non-COPD subjects with the intent of better understand their potential roles in driving local and
systemic inflammation.
Methods: This cross-sectional study analyzed data from 65 subjects: 31 with COPD confirmed by
spirometry and 34 non-COPD controls. All subjects underwent spirometry, plasma sample collection,
and bronchoscopy/BAL. Levels of 21 inflammatory cytokines were measured in the plasma (systemic
inflammation) and BAL (lung inflammation) using a multiplex assay.
Results: COPD subjects were overall older (median age 59 vs 36; p = <0.001) and had higher
incidence of history of pneumonia and hypertension; otherwise, groups were similar in respect to
gender, smoking history, history of asthma and other comorbidities. COPD subjects had higher
plasma levels of 12 measured cytokines (in pg/ml) as compared to non-COPD controls: tumor
necrosis factor (TNF)-α, 6.5 vs 3.7 (p = 0.005), interleukin (IL)-8, 5.1 vs 2.9 (p = 0.008), IL-21, 1 vs
0.4 (p = 0.006), IL-7, 5.9 vs 4.3 (p = 0.022), IL-10, 8.5 vs 5.1 (p = 0.036), interferon (IFN)-γ, 12.6 vs 9
(p = 0.021), IL-12p70, 1.8 vs 0.7 (p = 0.025), IL-2, 1.4 vs 0.9 (p = 0.014), IL-17A, 4.4 vs 1.7 (p = 0.026),
IL-23, 34.7 vs 11.3 (p = 0.026), macrophage inflammatory protein (MIP)-3 α (CCL20), 24.4 vs 19.8 (p
= 0.035), and fractalkine (CX3CL1), 68.9 vs 34.3 (p = 0.011). In contrast, cytokine levels in the BAL
fluid of COPD subjects were not elevated compared with controls.
Conclusion: Elevated levels of cytokines were identified in the plasma of COPD subjects when
compared to controls, supporting the role of these mediators as one of the mechanisms of systemic
inflammation in COPD. In contrast, lung cytokines were not elevated suggesting that inflammation
in the setting of COPD may not originate and/or perpetuate in the lungs, or that the BAL fluid is
not an optimal source of information when evaluating inflammation in COPD. Although the role of
these cytokines remains uncertain, anti-cytokine therapy might modulate inflammation in COPD and
perhaps improve outcomes.
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Introduction
Chronic obstructive pulmonary disease (COPD) is a growing
global epidemic condition with raising morbidity and mortality
as population age. It has been projected that COPD, which
ranked sixth as the cause of death in 1990, will become the third
leading cause of death worldwide by 2020 [1]. Smoking is the
most well-known risk factor for COPD; however, non-smokers
may develop chronic airflow obstruction through occupational
exposure to dust and chemicals and indoor pollution from
biomass. Other recognized risk factors are genetic predisposition
and low socioeconomic status [1].

in individual patients [2]. For example, COPD is associated
with cardiovascular diseases, osteoporosis, diabetes, and
metabolic syndrome more frequently than expected from
common etiological factors such as smoking, suggesting a causal
association between these comorbidities and the systemic
effects of COPD. This is a topic of increasing interest given the
large burden of hospitalizations and mortality associated with
this condition [3]. The mechanisms linking COPD to systemic
manifestations and comorbidities remains unelucidated, but a
potential mechanism is systemic inflammation [2].

COPD is characterized by progressive airflow limitation
from remodeling of small airways and destruction of lung
parenchyma. In addition to local pulmonary injury, it has been
increasingly recognized that COPD carries significant extra
pulmonary effects that may contribute to the severity of disease

Proposed mechanisms of systemic inflammation in COPD
include systemic oxidative stress, activation of circulating
inflammatory cells and increased levels of circulating
inflammatory cytokines [4, 5]. Inflammation in COPD involves
both innate immunity (neutrophils, macrophages, eosinophils,
mast cells, natural killer cells, gamma delta T cells, and
dendritic cells) and adaptive immunity (T and B lymphocytes),
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but also involves the activation of airway and alveolar epithelial
cells, endothelial cells, and fibroblasts. Cigarette smoke and
other irritants activate the release of multiple chemotactic
mediators, which attract circulating neutrophils, monocytes,
and lymphocytes into the lungs [4, 5]. Irritant-activated
epithelial cells produce inflammatory mediators, including
tumor necrosis factor (TNF) alpha, interleukin (IL)-1 beta,
IL-6, granulocyte-macrophage colony-stimulating factor
(GM-CSF), and IL-8. This inflammation persists even when
smoking is stopped, suggesting that there are self-perpetuating
mechanisms, although these have yet to be identified [6, 7]. It
is possible that memory T cells, bacterial colonization, and/or
autoimmunity may drive persistent inflammation in COPD [7].

and included HIV, non-HIV, COPD and non-COPD subjects. All
participants provided written informed consent and the study
was approved by the Institutional Review Board (IRB), approval
# 13.0442. HIV subjects were excluded for the purposes of our
study and 65 non-HIV subjects were selected; 31 with a diagnosis
of COPD and 34 non-COPD controls. The diagnosis of COPD
was made based on the current GOLD guidelines, defined as
FEV1/FVC ratio of less than 0.70 [1]. All subjects were seen in an
outpatient basis and were stable from a respiratory standpoint.
They underwent spirometry, blood sample collection and
outpatient bronchoscopy with BAL.

Several studies have explored the systemic inflammatory state
in COPD by demonstrating elevated levels of inflammatory
markers, inflammatory cells, and a variety of inflammatory
mediators such as cytokines in the serum and sputum of patients
with COPD [4, 8–16]. Based on our literature review, most
studies measuring local inflammatory responses in COPD have
been performed in induced sputum and not in bronchoalveolar
lavage (BAL) samples such as in our study. Cytokines are
extracellular signaling proteins that play important roles in
inflammatory and immune responses. Depending on their
effects promoting or inhibiting inflammatory mechanisms,
cytokines are normally classified as proor anti-inflammatory,
although it is not uncommon for many cytokines to exert both
types of effects depending on a variety of factors or conditions.
Chemokines are a family of structurally-related cytokines with
chemo-attractant properties that play a central role in the
recruitment of leukocytes to sites of inflammation. Elevated
levels of several pro-inflammatory cytokines, including TNF-α,
IL-1β, and IL-6; the chemokine IL-8, the anti-inflammatory
cytokine IL-10 and vascular endothelial growth factor (VEGF)
have been found to be elevated in the induced sputum of
individuals with COPD [17]. A pattern of elevated serum levels
of IL-6, IL-8, TNF-α, and VEGF has also been described in
different studies. The combined elevation of these cytokines in
the serum was shown to be significantly associated with severity
of disease [14]. The exact role of each cytokine is not completely
elucidated but some examples of studied effects are the skeletal
muscle weakness associated with IL-6, cachexia associated with
TNF-α and IL-1β and hypoxemia also associated with TNF-α
[18].

Spirometry was conducted following the guidelines of the
American Thoracic Society. A post-bronchodilator forced
expiratory volume in 1 second (FEV1)/forced vital capacity
(FVC) < 0.7 confirmed airflow limitation and the diagnosis of
COPD.

A more profound and detailed understanding of local and
systemic inflammatory responses in COPD is necessary in view
of the growing interest in studying it as a systemic condition
and in the search and development of new therapies [19]. The
purpose of this study was to compare inflammatory cytokine
profiles in the plasma and BAL of COPD and non-COPD
subjects.

Methods
Study design and subjects
This was a pilot cross-sectional study analyzing the data of
a subgroup of subjects included in the study “The Impact of
Oxidative Stress on HIV-Induced Lung Disease” conducted at
the University of Louisville in Louisville, Kentucky, USA. The
study enrolled 132 subjects from February 2014 to October 2016

Spirometry

Samples
Serum: Venous blood (4cc) was collected using Vacutainer
tubes and allowed to clot at room temperature. Following
centrifugation at 300 x g for 10 min, the serum was separated by
aspiration, aliquoted and stored frozen at -80°C until assayed.
Bronchoalveolar lavage: A bronchoscope was wedged into a
distal segment of a bronchus. After the administration of local
anesthesia (lidocaine 1% solution), a total of 180 ml of saline
solution in three 60 ml aliquots were instilled into a lobe of the
lung, with gentle aspiration after each aliquot. The lavage fluid
was filtered through sterile gauze and then centrifuged at
800 x g for 10 minutes. The cell pellet was resuspended in
Hanks’ balanced salt solution and the supernatants aliquoted
and stored at -80°C.
Cytokine measurements
Serum and BAL samples were thawed and centrifuged at 10,000
x g for 5 minutes prior to use in the assays. The concentrations
of twenty-one different cytokines and chemokines in plasma
and BAL samples were measured using Milliplex MAP High
Sensitivity Human T cell panel kits (HSCYTMAG-28SK, EMD
Millipore, Billerica, MA) according to the manufacturer’s
instructions. The measured cytokines/chemokines were: IL-1β,
IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12p70, IL-13, IL-17A,
IL-21, IL-23, IFN-γ, TNF-α, CCL3 (MIP-1α), CCL4 (MIP-1β),
CCL20 (MIP-3α), CXCL11 (I-TAC) and CX3CL1 (Fractalkine).
Cytokine/chemokine levels were reported in picogram per
milliliter (pg/mL). Cytokine levels in the BAL fluid were adjusted
for total protein to account for potential dilution.
Statistical analysis
Categorical variables were summarized with frequencies and
percentages and differences between groups were tested using
Chisquared or Fisher’s Exact tests. Continuous variables were
summarized with medians and interquartile ranges and the
Mann-Whitney U-test was used to test for differences between
groups. We considered a two-sided p value < 0.05 as statistically
significant. We used the software R version 3.3.2 for statistical
analysis.
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Results

Table 2. Plasma Cytokine Levels
(measured in Picogram per milliliter, pg/mL).

Subject Characteristics
The demographics and characteristics of the subjects are shown
in Table 1. Sixty-five subjects were included in the study; 31
with the diagnosis of COPD and 34 non-COPD controls. COPD
subjects were overall older than non-COPD (median age 59
vs 36; p = <0.001). History of bacterial pneumonia was more
common in the COPD group (45% vs 15%; p = 0.013) as was
the history of hypertension (55% vs 26%; p = 0.025). Groups
were otherwise similar in respect to gender, smoking history
and comorbidities such as asthma, diabetes and chronic kidney
disease.

COPD N=31
1.4 (1.2)

Non-COPD N=34
1.1 (0.7)

P-value
0.053

IL-6

1.4 (1.9)

0.7 (0.9)

0.069

TNFα

6.5 (2.2)

3.7 (1.9)

0.005

IL-8
GMCSF

5.1 (2.6)
35 (43.9)

2.9 (2.3)
21 (36.8)

0.008
0.081

IL-21

1 (0.6)

0.4 (0.7)

0.006

IL-7

5.9 (1.6)

4.3 (2.4)

0.022

Anti-inflammatory

IL-10

8.5 (6.1)

5.1 (2.9)

0.036

Chemokines

MIP-1α

13.6 (5.3)

12.2 (7)

0.515

MIP-1β

10.06 (4.04)

8.82 (6.32)

0.144

MIP-3α
I-TAC

24.4 (14.6)
14.5 (22.4)

19.8 (13.1)
12.2 (17.1)

0.035
0.317

FRACTALKINE

68.9 (29.8)

34.3 (27)

0.011

IFN-γ

12.6 (11.8)

9 (6.9)

0.021

IL-12p70

1.8 (2.3)

0.7 (1.3)

0.025

IL-2

1.4 (1.6)

0.9 (0.6)

0.014

4.4 (5.2)

1.7 (5.1)

0.026

34.7 (51.3)

11.3 (32.5)

0.026

Pro-inflammatory

Th1

Table 1. Baseline Characteristics of the Study Subjects.
Age, Median (IQR)
Sex: Male, n (%)
Current Smoker, n (%)
Alcohol Dependence or Abuse, n (%)
Asplenia, n (%)
History of Asthma, n (%)
History of Atelectasis, n (%)
History of Bacterial Pneumonia, n (%)
History of Bronchiectasis, n (%)
Cirrhosis, n (%)
Chronic Kidney Disease, n (%)
Dementia, n (%)
Diabetes Mellitus, n (%)
History of Gastric Reflux, n (%)
History of Hepatitis B, n (%)
History of Hepatitis C, n (%)
Home oxygen use, n (%)
Hypercholesterolemia, n (%)
Hypertension, n (%)
Hypertriglyceridemia, n (%)
Hypothyroidism, n (%)
Inflammatory Bowel Disease, n (%)
Presence of Lipodystrophy, n (%)
Peripheral Neuropathy, n (%)
Other Neurological Disease, n (%)
History of Pneumothorax, n (%)
FEV1/FVC, Median (IQR)
FEV1 (liters), Median (IQR)

COPD N=31
59 (11)
16 (52)
24 (77)
0 (0)
1 (3)
12 (40)
0 (0)
14 (45)
0 (0)
1 (3)
2 (6)
1 (3)
8 (26)
10 (33)
1 (3)
6 (19)
8 (30)
5 (16)
17 (55)
4 (13)
3 (10)
0 (0)
0 (0)
5 (16)
2 (6)
0 (0)
0.6 (0.1)
1.9 (1.2)

Non-COPD N=34
36 (22.5)
17 (50)
28 (82)
1 (3)
1 (3)
12 (38)
0 (0)
5 (15)
0 (0)
0 (0)
0 (0)
0 (0)
4 (12)
7 (21)
1 (3)
3 (9)
1 (9)
4 (12)
9 (26)
1 (3)
2 (6)
0 (0)
0 (0)
3 (9)
1 (3)
1 (3)
0.8 (0.1)
3.1 (1.2)

P-value
<0.001
>0.999
0.759
>0.999
>0.999
>0.999
>0.999
0.013
>0.999
0.477
0.224
0.484
0.204
0.272
>0.999
0.29
0.237
0.726
0.025
0.184
0.659
>0.999
>0.999
0.463
0.602
>0.999
<0.001
<0.001

Th17

IL-1β, Median (IQR)

IL-17A
IL-23

Th2

IL-4

2.1 (8.8)

0 (3)

0.316

IL-5

1.4 (1.9)

0.7 (1.4)

0.245

IL-13

1.8 (3.8)

1.4 (2.5)

0.803

IQR: interquartile range; COPD: chronic obstructive pulmonary disease IL: interleukin; TNF: tumor
necrosis factor, GMSCF: granulocyte macrophage colony-stimulating factor MIP: macrophage
inflammatory protein; I-TAC: interferon-inducible T-cell alpha chemoattractant; IFN: interferon

Table 3. Bronchoalveolar Lavage Cytokine Levels
(measured in Picogram per milliliter, pg/mL, adjusted for total protein).
Pro-inflammatory

IL-1β, Median (IQR)
IL-6
TNFα
IL-8
GMCSF
IL-21
IL-7

P-value
0.923

0.016 (0.04)

0.623

0.002 (0)
0.534 (0.52)

0.006 (0.01)
0.285 (0.47)

0.009
0.198

0.006 (0)

0.007 (0.01)

0.195

0 (0)

0 (0)

0.415

0 (0)

0 (0.02)

0.210

0 (0)

0 (0)

0.497

0.028 (0.03)

0.893

0 (0.01)

0.005 (0.02)

0.168

0 (0.03)

0.018 (0.13)

0.172

0 (0.02)

0.003 (0.02)

0.961

FRACTALKINE

0 (0)

0 (0.1)

0.097

IFN-γ

0 (0)

0 (0)

0.154

0 (0)

0 (0)

0.149

IL-2

0 (0)

0 (0)

0.699

Th17

IL-17A
IL-23

0 (0)
0 (0)

0 (0)
0 (0)

0.221
0.221

Th2

IL-4

0.012 (0.04)

0 (0.01)

0.230

0 (0)

0 (0)

0.330

0 (0)

0 (0)

0.154

Chemokines

IL-10
MIP-1α
MIP-1β
MIP-3α
I-TAC

BAL fluid cytokine levels are shown in Table 3. None of the
twenty-one measured cytokines was found to have significantly
elevated levels in COPD subjects in comparison with non-COPD
subjects. Level of TNF-α was found to be significantly elevated
in non-COPD subjects.

Non-COPD N=34
0 (0)

0.013 (0.03)

0.023 (0.02)

Anti-inflammatory

IQR: interquartile range; COPD: chronic obstructive pulmonary disease
FEV1: forced expiratory volume in one second; FVC: forced vital capacity

Cytokine Levels
Plasma cytokine levels are shown in Table 2. COPD subjects
had significantly higher mean plasma levels of twelve of the
twentyone measured cytokines: TNF-α, IL-8, IL-21, IL-7,
IL-10, IFN-γ, IL-12p70, IL-2, IL-17A, IL-23, MIP-3α, and
fractalkine. Levels of the remaining measured plasma cytokines
in comparison to non-COPD subjects were not significantly
different.

COPD N=31
0 (0)

Th1

IL-12p70

IL-5
IL-13

IQR: interquartile range; COPD: chronic obstructive pulmonary disease IL: interleukin; TNF: tumor
necrosis factor, GMSCF: granulocyte macrophage colony-stimulating factor MIP: macrophage
inflammatory protein; I-TAC: interferon-inducible T-cell alpha chemoattractant; IFN: interferon

Correlation between cytokine level and pulmonary
function
As shown in Table 4, BAL levels of GMSCF and TNF-α were
positively correlated with FEV1/FVC. In the plasma, levels of
fractalkine, IL-12p70, IL-17A, IL-2, IL-21, IL-6, IL-7, IL-8 and
TNF-α were negatively correlated.
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Table 4. Correlation between cytokine level and FEV1/FVC.

Correlation (BAL)

P-value

Correlation (Plasma)

P-value

GMSCF

0.319

0.048

-0.206

0.209

FRACTALKINE

0.184

0.262

-0.438

0.005

IL-12p70

0.061

0.713

-0.455

0.004

IL-17A

0.022

0.892

-0.325

0.043

IL-2

-0.085

0.606

-0.343

0.033

IL-21

0.108

0.514

-0.363

0.023

IL-6

-0.007

0.966

-0.389

0.014

IL-7

0.073

0.658

-0.442

0.005

IL-8

-0.124

0.451

-0.518

0.001

TNFα

0.426

0.007

-0.540

<0.001

BAL: bronchoalveolar lavage; GMSCF: granulocyte macrophage colony-stimulating factor; IL:
interleukin; TNF: tumor necrosis factor

BAL levels of GMSCF, IFN-γ, IL-17A and TNF-α were positively
correlated with FEV1. In the plasma, levels of Fractalkine, IL-8
and TNF-α were negatively correlated with FEV1. This is shown
in Table 5.

Table 5. Correlation between cytokine level and FEV1.

Correlation (BAL)

P-value

Correlation (Plasma)

P-value

GMSCF

0.454

0.004

0.063

0.701

FRACTALKINE

0.159

0.334

-0.360

0.024

IFNγ

0.353

0.027

-0.141

0.390

IL-17A

0.345

0.031

-0.147

0.372

IL-8

-0.026

0.877

-0.576

<0.001

0.367
0.021
-0.469
0.003
TNFα
BAL: bronchoalveolar lavage GMSCF: granulocyte macrophage colony-stimulating factor, IFN:
interferon; IL: interleukin; TNF: tumor necrosis factor

Discussion
Our study found significantly elevated levels of twelve cytokines
and chemokines in the systemic circulation of subjects with
COPD in comparison with non-COPD controls. In the BAL,
cytokine levels were not different in COPD and non-COPD,
except for TNF-α, which levels were elevated in the nonCOPD group. COPD is associated not only with an abnormal
inflammatory response of the lung parenchyma but also with
systemic inflammation implicated in the pathogenesis of many
of the comorbidities linked to this condition including weight
loss, skeletal muscle dysfunction, cardiovascular disease,
depression, and osteoporosis, making this a popular study
subject. Known mechanisms of local inflammation in COPD
include oxidative stress, activation of resident inflammatory
cells and increased production of proinflammatory cytokines.
In local immune (e.g. macrophages) and non-immune cells
(e.g. epithelial cells), it is known that cigarette smoke and air
pollutants are triggers for these local mechanisms. On the other
hand, the origin of systemic inflammation in COPD is not yet
completely elucidated. The hypothesis that inflammatory cells
“spill-over” into the systemic circulation has been explored,
however, it has not been proven [20–22]. Smoking, per se, has
been explored as a mechanism for systemic inflammation in
COPD. Some cytokines appear to be elevated as a consequence
of smoking, particularly, IFN-γ, TGF-b, IL-8 and MCP-1 [14].
The inflammatory process, however, seems to continue despite
smoking cessation. This is supported by evidence of persistent
presence of inflammatory cells and mediators and continued despite slower - deterioration of lung function in ex-smokers [6,
7, 23, 24].

Similarly to our findings, elevated levels of several cytokines in
the systemic circulation of COPD subjects have been previously
demonstrated in multiple studies. Some of the cytokines
commonly found to be elevated were IL1-b, IL-6, IL-16, IL-8,
TNF-α and VEGF [11, 14–16, 23, 25]. Selvarajah et al. measured
fourteen cytokines in serum from never-smokers, ex-smokers,
current smokers, and COPD subjects (GOLD stages 1-3) and
found that the combined - not individual - increase of certain
cytokines in COPD subjects was associated with disease
severity, indicating that patterns of cytokine expression might
be more relevant [14]. Aaron et al. measured sputum and
serum cytokine levels in past and current smokers with COPD,
smokers with no COPD, and non-smokers with COPD in three
different occasions. Systemic and sputum biomarkers were
associated with clinical variables that predict severity in COPD,
but also showed a high degree of intra-subject variability by
using repeated biomarker measurements over time, suggesting
that one-time measurements may not be diagnostically reliable.
As previously mentioned, the association between severity
of disease and cytokine levels has been explored [14–16, 23].
According to GOLD guidelines FEV1/FVC is used for diagnosis
of COPD and FEV1 is used to classify severity of disease [1]. In
our study, we found significant negative correlation between
levels of nine plasma cytokines and FEV1/FVC and three
cytokines and FEV1.
We also measured cytokine levels in BAL fluid and surprisingly
found none of the cytokines or chemokines to be significantly
elevated in COPD subjects in comparison with non-COPD.
In fact, level of TNF-α was found to be elevated in the nonCOPD group. Before we explore these findings, it is important
to highlight that most studies exploring local inflammation
in COPD have utilized induced sputum and not BAL samples
as we were able to perform in our study. In addition, many of
the studies using BAL measurements were conducted with the
purpose of comparing local cytokine profiles in COPD versus
asthma and not necessarily with the aim of contrasting BAL with
serum levels such as we aimed with our analysis. Therefore, we
consider that our study took a distinct approach when seeking a
better understanding of inflammation in COPD, enabling one to
compare BAL (local) versus plasma (systemic) in COPD versus
non-COPD subjects.
Multiple studies have previously explored local inflammation
in COPD by analysis of induced sputum with measurement
of different cytokine levels. The findings have been overall
inconsistent when sputum or BAL levels were compared to
serum levels, as well as when levels were compared between
COPD and non-COPD groups [9, 12, 15, 23, 26, 27]. Considering
that we found low levels of locally present cytokines in COPD
- which differs from most studies in our literature search - we
bring the following points to discussion. First, inflammation
in the setting of COPD may not originate and/or perpetuate in
the lungs. As mentioned above, previous studies have shown
that some COPD subjects continue to have decline in lung
function despite smoking cessation [6, 7, 23, 24]. This suggests
that inflammation in COPD could be generated systemically
and not locally, which could potentially, or at least partially,
explain the fact that to this day we have not found effective local
therapies that prevent decline in lung function and significantly
decrease morbidity and mortality in COPD. Second, BAL fluid
may not be the optimal source of information when evaluating
inflammation in COPD and selecting the correct biological fluid
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is crucial in the search for targeted therapies.
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